-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Head-To-Head Contrast: Arcellx (NASDAQ:ACLX) Versus Freeline Therapeutics (NASDAQ:FRLN)
Head-To-Head Contrast: Arcellx (NASDAQ:ACLX) Versus Freeline Therapeutics (NASDAQ:FRLN)
Arcellx (NASDAQ:ACLX – Get Rating) and Freeline Therapeutics (NASDAQ:FRLN – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.
Insider and Institutional Ownership
92.3% of Arcellx shares are held by institutional investors. Comparatively, 58.5% of Freeline Therapeutics shares are held by institutional investors. 1.9% of Freeline Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Get Arcellx alerts:Analyst Ratings
This is a breakdown of current ratings and target prices for Arcellx and Freeline Therapeutics, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Arcellx | 0 | 0 | 8 | 0 | 3.00 |
Freeline Therapeutics | 0 | 1 | 4 | 0 | 2.80 |
Profitability
This table compares Arcellx and Freeline Therapeutics' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Arcellx | N/A | -68.99% | -42.26% |
Freeline Therapeutics | N/A | -101.38% | -67.17% |
Valuation & Earnings
This table compares Arcellx and Freeline Therapeutics' revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Arcellx | N/A | N/A | -$64.97 million | ($44.41) | -0.72 |
Freeline Therapeutics | N/A | N/A | -$140.39 million | ($2.12) | -0.27 |
Arcellx is trading at a lower price-to-earnings ratio than Freeline Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Arcellx beats Freeline Therapeutics on 6 of the 10 factors compared between the two stocks.
About Arcellx
(Get Rating)
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
About Freeline Therapeutics
(Get Rating)
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.
Receive News & Ratings for Arcellx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcellx and related companies with MarketBeat.com's FREE daily email newsletter.
Arcellx (NASDAQ:ACLX – Get Rating) and Freeline Therapeutics (NASDAQ:FRLN – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.
纳斯达克:ACLX-GET评级)和Freeline治疗公司(纳斯达克:FRLN-GET评级)都是小盘医疗公司,但哪只股票更好?我们将根据两家公司的分析师建议、机构持股、估值、盈利能力、股息、风险和收益的强弱对它们进行比较。
Insider and Institutional Ownership
内部人与机构持股
92.3% of Arcellx shares are held by institutional investors. Comparatively, 58.5% of Freeline Therapeutics shares are held by institutional investors. 1.9% of Freeline Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Arcellx 92.3%的股份由机构投资者持有。相比之下,Freeline治疗公司58.5%的股份由机构投资者持有。Freeline治疗公司1.9%的股份由内部人士持有。强大的机构持股表明,大型基金管理公司、捐赠基金和对冲基金相信,一家公司有望实现长期增长。
Analyst Ratings
分析师评级
This is a breakdown of current ratings and target prices for Arcellx and Freeline Therapeutics, as provided by MarketBeat.
这是MarketBeat提供的Arcell和Freeline治疗公司的当前评级和目标价格的细目。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Arcellx | 0 | 0 | 8 | 0 | 3.00 |
Freeline Therapeutics | 0 | 1 | 4 | 0 | 2.80 |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
阿尔塞克斯 | 0 | 0 | 8 | 0 | 3.00 |
Freeline治疗公司 | 0 | 1 | 4 | 0 | 2.80 |
Profitability
盈利能力
This table compares Arcellx and Freeline Therapeutics' net margins, return on equity and return on assets.
此表比较了Arcell和Freeline治疗公司的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
Arcellx | N/A | -68.99% | -42.26% |
Freeline Therapeutics | N/A | -101.38% | -67.17% |
净利润率 | 股本回报率 | 资产回报率 | |
阿尔塞克斯 | 不适用 | -68.99% | -42.26% |
Freeline治疗公司 | 不适用 | -101.38% | -67.17% |
Valuation & Earnings
估值与收益
This table compares Arcellx and Freeline Therapeutics' revenue, earnings per share (EPS) and valuation.
此表比较了Arcell和Freeline治疗公司的收入、每股收益(EPS)和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Arcellx | N/A | N/A | -$64.97 million | ($44.41) | -0.72 |
Freeline Therapeutics | N/A | N/A | -$140.39 million | ($2.12) | -0.27 |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
阿尔塞克斯 | 不适用 | 不适用 | -6,497万元 | ($44.41) | -0.72 |
Freeline治疗公司 | 不适用 | 不适用 | -1.4039亿美元 | ($2.12) | -0.27 |
Arcellx is trading at a lower price-to-earnings ratio than Freeline Therapeutics, indicating that it is currently the more affordable of the two stocks.
Arcell的市盈率低于Freeline治疗公司,这表明它目前是两只股票中更负担得起的一只。
Summary
摘要
Arcellx beats Freeline Therapeutics on 6 of the 10 factors compared between the two stocks.
Arcell在两只股票之间的10个因素中有6个击败了Freeline治疗公司。
About Arcellx
关于Arcellx
(Get Rating)
(获取评级)
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Arcell,Inc.是一家临床阶段的生物技术公司,致力于为癌症和其他不治之症患者开发各种免疫疗法。该公司主要的ddCAR候选产品是CART-ddBCMA,这是一种治疗复发或难治性(r/r)多发性骨髓瘤(MM)患者的第一阶段临床试验。该公司还在开发ACLX-001,这是一种由ARC-T细胞和针对BCMA的双价SPARX蛋白组成的免疫治疗组合,用于治疗r/r MM;ACLX-002和ACLX-003用于治疗r/r急性髓系白血病(AML)和骨髓增生异常综合征(MDS);以及其他AML/MDS候选产品,以及实体肿瘤计划。该公司前身为Encarta治疗公司,并于2016年1月更名为Arcell,Inc.。Arcell,Inc.成立于2014年,总部位于马里兰州盖瑟斯堡。
About Freeline Therapeutics
关于Freeline治疗公司
(Get Rating)
(获取评级)
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.
Freeline治疗控股公司是一家临床阶段的生物技术公司,为患有遗传性全身性衰弱疾病的患者开发变革性腺相关病毒(AAV)载体介导的基因疗法。该公司的先进候选产品是verbrinacogene setparvovec(FLT180a),这是一种用于治疗血友病B的成年男性候选基因治疗产品,目前正处于1/2阶段临床试验。该公司的产品还包括治疗Fabry病处于1/2阶段临床试验的FLT190,以及治疗1型高谢病的候选肝脏基因治疗产品FLT201。此外,它还在系统基因治疗的各种适应症上制定了研究计划。该公司成立于2015年,总部设在英国史蒂夫尼奇。
Receive News & Ratings for Arcellx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcellx and related companies with MarketBeat.com's FREE daily email newsletter.
接受Arcell Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收Arcell和相关公司的最新新闻和分析师评级的每日简明摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧